MedTrace Logo

A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

NCT01395004 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-09-09

No results posted yet for this study

Summary

The purpose of this study was to assess safety and efficacy at months 3 and 6 in patients with Langerhans Cell Histiocytosis given daily oral doses of GSK2110183.

Conditions

  • Langerhans Cell Histiocytosis

Interventions

DRUG

GSK2110183

GSK2110183 was orally administered at 125 mg once daily.

Sponsors & Collaborators

Principal Investigators

  • Shannon R Morris, MD, PhD · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01395004 on ClinicalTrials.gov